Sharp Therapeutics Appoints Co-Founder Of National Gaucher Foundation And Clinical Researcher Robin Ely, M.D., To Advisory Board

Core Insights - Sharp Therapeutics Corp. has appointed Dr. Robin Ely, a prominent figure in Gaucher disease advocacy and research, to its Advisory Board, enhancing its expertise in orphan diseases [1][3]. Company Overview - Sharp Therapeutics is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics for genetic diseases, aiming to restore function in mutated proteins through conventional pill-based medicines [4]. Advisory Board Composition - Dr. Ely's appointment is part of a broader strategy to strengthen the Advisory Board, which includes other distinguished experts in the field of rare diseases and therapeutic development [3][6]. Clinical Development Plans - The company is preparing to initiate clinical studies later in the year, with a focus on its lead program '901' for Gaucher disease and a growing pipeline for other genetically defined indications [3].